Column | Powerful new weight-loss drug may also ease knee pain, major study finds

Live updates

1. 1h ago

   Retatrutide shows significant knee osteoarthritis pain relief in major clinical trials

   Eli Lilly's experimental triple-hormone drug retatrutide significantly reduced knee osteoarthritis pain and improved physical function in two Phase 3 clinical trials involving adults with obesity. The findings were presented at the American College of Rheumatology Convergence 2026. Retatrutide, which targets GLP-1, GIP, and glucagon receptors, is being studied for both weight loss and metabolic conditions. Researchers reported that some patients experienced near-complete resolution of chronic knee pain. The drug is not yet approved for any indication.

   Why it matters

   Osteoarthritis is a leading cause of disability, and excess weight is a primary risk factor for knee joint degeneration. Current treatments focus on symptom management, physical therapy, or joint replacement. A pharmacotherapy that simultaneously drives substantial weight loss and directly reduces joint inflammation or pain signaling would represent a major shift in care. Lilly is also presenting data on Zepbound (tirzepatide) combined with Taltz (ixekizumab) for psoriatic arthritis with obesity, highlighting a broader strategy at the intersection of immunology and metabolism.

   What is confirmed

   • Retatrutide significantly improved knee osteoarthritis pain and physical function in two Phase 3 clinical trials.
   • The trials enrolled adults with obesity and knee osteoarthritis.
   • Data were presented at the American College of Rheumatology Convergence 2026.
   • Retatrutide is an experimental triple-hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors.
   • Eli Lilly is the manufacturer developing retatrutide.
   • The drug is not yet approved by regulatory agencies for any indication.

   Still unconfirmed

   • Some patients experienced near-complete resolution of chronic knee pain.
   • Retatrutide may wipe out chronic knee pain in some patients.

   What to watch next

   • Regulatory filing timeline for retatrutide for obesity or osteoarthritis indications
   • Publication of full Phase 3 trial results in a peer-reviewed journal
   • Safety and tolerability data from the knee osteoarthritis trials
   Sources used for this update (11)

   1. www.liverpoolfc.com — Liverpool FC — Homepage
   2. Eli Lilly — Lilly to showcase new retatrutide, Taltz (ixekizumab) and Zepbound (tirzepatide) data at ACR Convergence 2026, advancing science at the intersection of rheumatologic conditions and obesity
   3. Medscape — Retatrutide Improves Knee OA Pain, Physical Function
   4. The Washington Post — Column | Powerful new weight-loss drug may also ease knee pain, major study finds
   5. Fox News — New weight-loss drug wipes out chronic knee pain in some patients, researchers say
   6. Everyday Health — Retatrutide ‘Significantly’ Eases Knee Pain in People With Obesity, Studies Show
   7. Yahoo — Eli Lilly Says Taltz/Zepbound Combo Shows Long-Term Efficacy in Psoriatic Arthritis Trial
   8. Eli Lilly — New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy, patient-reported and metabolic outcomes at one year in adults with psoriatic arthritis and obesity
   9. Northwestern Now News — Experimental weight-loss drug eases painful knee osteoarthritis in two clinical trials
   10. Medical News Today — New weight-loss drug eases knee osteoarthritis pain in major trials
   11. grandforksgazette.ca — COLUMN: Bruins Split Weekend, Starting With a Big Finish in Merritt | Grand Forks Gazette
   confidence 92%